MTOR and diabetes mellitus: Thus, further efforts should focus on the development of mTOR-targeting therapeutics outside of these two modalities, such as truly mTORC1-specific inhibitors for use in diabetes, neurodegeneration, and life-span extension or tissue-specific mTORC1 agonists for use in muscle wasting diseases and immunotherapy.